PEPGEN INC

PEPGNASDAQ

🏆 #3833 by market capEarnings Nov 10US Equity

$654.00▼ $50.16 (−7.67%)

Simulated price

🔔

Track PEPG

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 7.7%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$162M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

No chart data available for PEPG.

Trading Snapshot

Day Range: $645.55 – $663.39
52-Week Range: $1.31 – $7.80
Volume: $3.06B
Avg Volume: $3.97B
Shares Outstanding: 69.2M
Next Earnings: Nov 15, 2026

Fundamentals Snapshot

Annual Revenue: $22M
Last Q Revenue: $6M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.30
Dividend Yield: —
Dilution (1yr): +29.5%

Why Investors Own PEPG

✓High-growth profile — revenue up +3.4% YoY with expanding US Equity exposure.
✓Healthy economics — 45% gross margin and 27% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PEPGEN INC

PEPG

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$94M▼ −4.2% YoY

Free Cash Flow

−$82M▼ −1.2% YoY

Shares Outstanding

42.2M▲ +29.5% YoY

Net Cash

$44M▲ +$13M YoY

StockOtter · stockotter.space

About PEPGEN INC

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

🦦